Frier Levitt partner Edgar Asebey has been interviewed by Pharmacy Times in, “The Future of FDA Enforcement: How Artificial Intelligence Is Changing Drug Advertising Compliance.” In this discussion, Edgar explores how artificial intelligence (AI) could change FDA enforcement and oversight of direct-to-consumer (DTC) advertising.
Edgar explains that while pharmaceutical advertising budgets have expanded dramatically since the late 1990s, the FDA’s resources have not kept pace, creating gaps in compliance enforcement. To address this, the current administration is leveraging AI technologies to enhance monitoring, streamline review processes, and even automate the issuance of warning letters.
Edgar predicts that within five years, these advancements could usher in a new era of proactive regulatory oversight, driving companies to strengthen compliance and better protect consumers and patients.
Watch or read the interview here: https://www.pharmacytimes.com/view/the-future-of-fda-enforcement-how-artificial-intelligence-is-changing-drug-advertising-compliance
